evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,587 questions · 5,761 findings · 495 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1,011 · 17.5%GRADE not reported 1,797 · 31.2%Very low 1,100 · 19.1%Low 1,052 · 18.3%Moderate 649 · 11.3%High 152 · 2.6%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

RISPERIDONE DEPOT vs RISPERIDONE

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in leaving the study early: Any reason ‐ short term compared with ORAL RISPERIDONE (moderate certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs RISPERIDONE

Adverse events: Movement disorder ‐ any extra pyramidal symptoms ‐ short term · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in adverse events: Movement disorder ‐ any extra pyramidal symptoms ‐… compared with ORAL RISPERIDONE (moderate certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs RISPERIDONE

Adverse events: Specific ‐ prolactin‐related · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in adverse events: Specific ‐ prolactin‐related compared with ORAL RISPERIDONE (moderate certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs QUETIAPINE

Leaving the study early · patients with schizophrenia

RISPERIDONE DEPOT probably leads to lower leaving the study early: Any reason ‐ long term compared with ORAL QUETIAPINE (moderate certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs QUETIAPINE

Adverse events: General ‐ serious · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in adverse events: General ‐ serious Recorded at each compared with ORAL QUETIAPINE (low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs QUETIAPINE

Adverse events: Movement disorder ‐ any extra pyramidal symptom · patients with schizophrenia

RISPERIDONE DEPOT may leads to higher adverse events: Movement disorder ‐ any extra pyramidal symptom compared with ORAL QUETIAPINE (low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs QUETIAPINE

Adverse events: Specific ‐ prolactin‐related · patients with schizophrenia

RISPERIDONE DEPOT may leads to higher adverse events: Specific ‐ prolactin‐related Reported by… compared with ORAL QUETIAPINE (low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ARIPIPRAZOLE

Relapse · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in global state: Relapse (any reason) ‐ long term Assessed by 5 blinded… compared with ORAL ARIPIPRAZOLE (low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ARIPIPRAZOLE

Leaving the study early · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes leaving the study early: Any reason ‐ long term compared with ORAL ARIPIPRAZOLE (very low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ARIPIPRAZOLE

Adverse events: General ‐ serious Unclear how these events were reported · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes adverse events: General ‐ serious Unclear how these events were… compared with ORAL ARIPIPRAZOLE (very low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ARIPIPRAZOLE

Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Movement disorder ‐ any extra pyramidal symptoms compared with ORAL ARIPIPRAZOLE (very low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ARIPIPRAZOLE

Weight gain · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in adverse events: Specific ‐ weight increase compared with ORAL ARIPIPRAZOLE (low certainty).

1 finding from 1 review